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Epidermal growth factor receptor (EGFR) is often overexpressed in tumors and has been
associated with poor prognosis in some cancer types. The introduction of inhibitors of
EGFR, such as erlotinib, represents an important recent advance in the targeted treatment
of cancer. Several studies have evaluated inhibitors of EGFR in combination with radio-
therapy, and a strong biologic rationale exists for the use of this combination in certain
cancer types, including head and neck squamous cell carcinoma, non-small cell lung can-
cer, glioblastoma, esophageal cancer, and pancreatic cancer. Preclinical and clinical studies
are underway to evaluate the combination of erlotinib with radiotherapy.To date, the results
suggest that this approach is at least feasible and may result in modest improvement in
outcomes compared with either modality alone.
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INTRODUCTION
Erlotinib is a small molecule inhibitor that reversibly targets the
tyrosine kinase activity of the epidermal growth factor receptor
(EGFR). EGFR is overexpressed and/or mutated in many cancer
types, and its activation triggers pathways involved in cell growth
and proliferation. Overexpression of EGFR in tumors often corre-
lates with poor prognosis because of its involvement in tumor pro-
gression, angiogenesis, migration, and metastasis (Yarden, 2001).
Some tumor types, such as head and neck squamous cell carci-
noma (HNSCC), typically exhibit high levels of EGFR expression
(Mendelsohn, 2001). At least a third of tumors exhibit EGFR dys-
regulation or overexpression, although the expression of EGFR
does not always correlate with response to therapeutic EGFR
inhibitors (Mendelsohn, 2001; Harari, 2004). In the United States,
erlotinib is approved asmonotherapy for previously treated locally
advanced or metastatic non-small cell lung cancer (NSCLC) and
in combination with gemcitabine for the ﬁrst-line treatment of
metastatic pancreatic cancer. Many clinicians are incorporating
the use of erlotinib into treatment for other indications as well,
particularly in the metastatic setting.
A pivotal trial in establishing a potential role for combining
EGFR inhibition with radiotherapy (RT) was a randomized phase
III trial that compared the use of cetuximab and RT with RT-
alone in locoregionally advanced HNSCC (Bonner et al., 2006).
This study demonstrated a signiﬁcant improvement in overall sur-
vival (OS) and local control in the experimental arm. A recent
update of this study demonstrated that the improvements were
durable with extended follow-up (Bonner et al., 2010). The 5-
year OS for 211 patients assigned to the combination arm was
45.6% compared with 36.4% for the 213 patients receiving RT
monotherapy. Median OS for patients in the combination arm
was 49.0months compared with 29.3months for patients assigned
to RT-alone (hazard ratio= 0.73; 95% conﬁdence interval, 0.56–
0.95; P = 0.018). Moreover, with the exception of acneiform rash
and infusion reactions, grade ≥3 adverse events associated with
the combination of cetuximab and RT did not appear to be worse
than those associated with RT-alone (Bonner et al., 2006).
Erlotinib has been evaluated in combination with RT in a num-
ber of cancer types, and several studies are ongoing. This report
describes the biologic rationale for combining erlotinibwith RT, as
well as the preclinical and clinical evidence that supports the use
of this combination in various tumor types, including HNSCC,
NSCLC, glioblastoma (GBM), esophageal cancer, and pancreatic
cancer.
RATIONALE FOR COMBINING ERLOTINIB WITH RT
A strong rationale may exist for combining erlotinib with RT.
Erlotinib helps disrupt cell growth pathways (Figure 1) and
enhances the sensitivity of cells to the effects of RT (Chinnaiyan
et al., 2005; Nyati et al., 2006; Baumann et al., 2007; Tortora et al.,
2007; Marshall, 2011). It is also possible that RT enhances the
effectiveness of erlotinib by cytoreducing the tumor and creat-
ing a hypoxic environment (Tortora et al., 2007). In addition, the
rationale that supports combining a systemic agent and local ther-
apy for maximal effect is applicable to this combination. Finally,
toxicities associated with erlotinib and with RT are generally,
although not completely, non-overlapping, which enables their
concomitant use.
The optimal timing of the administration of RT and erlotinib
has yet to be determined. Various trials have been designed to
evaluate erlotinib given before, concurrently, and/or following the
RT component of treatment. The potential beneﬁt of using sys-
temic chemotherapy or targeted agents, such as bevacizumab, in
combination with erlotinib and RT also needs to be established.
PRECLINICAL DATA WITH ERLOTINIB AND RT
Several lines of preclinical evidence support the combination
of erlotinib and RT in various cell types (Chinnaiyan et al.,
2005). Erlotinib enhances the radiation response at several lev-
els, including cell cycle arrest, apoptosis induction, accelerated
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FIGURE 1 | Epidermal growth factor receptor (EGFR) activation of signal
transduction pathways and points of inhibition by targeted therapies.
The activation of EGFR on tumor cells leads to phosphorylation of tyrosine
residues in the kinase domain of the receptor and subsequent activation of
the Ras/Raf/MEK/ERK, JAK–STAT, or PI3K/Akt/mTOR pathways. In turn, these
pathways result in the activation of genes related to angiogenesis, cell
proliferation, metastasis, and adhesion. Akt, v-akt murine thymoma viral
oncogene homolog 1; EGFR, epidermal growth factor receptor; ERK,
extracellular regulated kinase; JAK, Janus kinase; MEK, MAP kinase–ERK
kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol
3-kinase; Ras, rat sarcoma viral oncogene homolog; Raf, v-raf-1 murine
leukemia viral oncogene homolog 1; SRC, Rous sarcoma oncogene; STAT,
signal transducer, and activator of transcription;TKIs, tyrosine kinase inhibitors.
Adapted from Box 2 in Nyati et al. (2006) and Figure 2 in Marshall (2011).
cellular repopulation, and DNA damage repair. Chinnaiyan et al.
(2005) reported that erlotinib modulated the radiation response
by inﬂuencing cell cycle kinetics and apoptosis. Erlotinib appeared
to modify the effect of RT on EGFR autophosphorylation and
Rad51 expression. In addition, erlotinib in combination with RT
reduced the number of cells in S phase while increasing the level
of apoptosis and promoting an increase in sensitivity to RT. In
tumor xenografts, erlotinib combinedwith RT dramatically inhib-
ited tumor growth (Figure 2), and microarray analysis indicated
that the addition of erlotinib inﬂuenced the expression of radia-
tion response genes from several functional classes, including cell
cycle arrest and DNA damage repair (Chinnaiyan et al., 2005).
In a second preclinical study involving three human cancer
cell lines with low, moderate, and very high EGFR expression,
the extent of erlotinib-induced radiosensitization was found to be
proportional to the expression and autophosphorylation of EGFR
(Kim et al., 2005a). The cell line A431, which expresses very high
levels of EGFR, demonstrated the highest degree of radioresis-
tance, and treatment with erlotinib increased the extent of G1
arrest and augmented apoptosis in these cells.
Erlotinib and higher-dose RT have been shown to achieve an
additive antitumor effect in a xenograft model of GBM (Sarkaria
et al., 2006). In this preclinical study, an orthotopicGBMxenograft
exhibiting EGFR ampliﬁcation was transplanted into athymic
mice;mice with established intracranial tumors were subsequently
randomized to sham (control), RT, erlotinib, or erlotinib and RT.
The combination of erlotinib and intensiﬁed RT (20Gy/5 days),
but not lower-dose radiation (12Gy/12 days), produced a survival
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FIGURE 2 | In vivo activity of erlotinib with or without
radiotherapy (RT) in tumor xenografts. H226 (106) or UM-SCC6
(106) cells were injected subcutaneously into the ﬂanks of athymic
mice as described. Mice were treated with erlotinib (0.8mg daily via
oral gavage), RT (2-Gy fraction twice per week), or the combination
for 3weeks. Points, mean tumor size (mm3; six mice per treatment
group). Reprinted with permission from Chinnaiyan et al. (2005,
Figure 6).
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FIGURE 3 | Primary tumor growth after 10days of treatment with
single agents and combinations (10 mice per treatment group). Bars
denote SD. Values above the columns concern comparisons with the
controls; other values concern comparisons between two following
columns. *P <0.05; †P <0.01; ‡P <0.001; NS, non-signiﬁcant (P >0.05);
RT, radiotherapy. Reprinted by permission from (Bozec et al., 2008),
copyright 2008.
beneﬁt beyond that observed with either modality administered
as monotherapy.
In addition, the antiangiogenic agent bevacizumab in com-
bination with erlotinib and RT was investigated in a preclinical
study of the human vascular endothelial growth factor–secreting
HNSCC cell line CAL33, which also has a high expression level
of EGFR (Bozec et al., 2008). Cells were injected as orthotopic
xenografts into the mouth ﬂoors of nude mice. Each agent was
administered alone and in combination. With the administration
of bevacizumab and erlotinib, tumor growth was decreased signif-
icantly compared with controls (Figure 3). When RT was added,
tumor growth was almost completely eliminated, and the total
number of pathologically positive lymph nodes was signiﬁcantly
reduced compared with controls.
Together, results of these preclinical studies highlight the poten-
tial beneﬁt of combining RT with EGFR inhibition in clinical
practice, a strategy that is under investigation in multiple clinical
trials.
CLINICAL DATA IN HNSCC
The treatment of patients with head and neck cancer has been con-
tinually evolving. Treatment of patients with unresectable tumors
has moved from deﬁnitive RT to chemoradiotherapy in the last
decade. In HNSCC, EGFR overexpression has been demonstrated
in 95–100% of tumors (Salomon et al., 1995). Erlotinib has been
evaluated in the treatment of head and neck cancers, demon-
strating modest single-agent activity in the setting of metastatic
refractory HNSCC [response rate (RR), 4.3%; stable disease (SD),
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38.3% for a median duration of 16.1 weeks; Soulieres et al., 2004].
In the salvage setting, erlotinib has been combined with docetaxel
and cisplatin (RR, 67%; disease control rate, 95%) with good
results (Kim et al., 2007).
Several phase II and phase III trials have evaluated the combi-
nation of erlotinib and RT in the deﬁnitive treatment of HNSCC
(Table 1), although published data are limited. Erlotinib in combi-
nation with cisplatin and RT was evaluated in a phase I/II study of
patients with stage III and IV HNSCC (Herchenhorn et al., 2010).
A standard chemoradiotherapy regimenwas used,with RT admin-
istered for 5 days, for a total dose of 70.2Gy over 8weeks, and
cisplatin administered at a dose of 100mg/m2 every 3weeks. In the
dose-escalation phase, no dose-limiting toxicity was observed for
erlotinib at 150mg/day; this dosage was subsequently employed
in the phase II trial. Twenty-three of the 31 patients treated at
this dosage had pathologic complete responses (CRs) as assessed
by imaging and biopsy. At a median follow-up of 37months, 3-
year progression-free survival (PFS) and OS rates were 61 and
72%, respectively. Grade 3 and 4 adverse events included in-ﬁeld
dermatitis (n = 16), nausea (n = 15), emesis (n = 12), dyspha-
gia (n = 11), mucositis (n = 9), xerostomia (n = 9), acneiform
rash (n = 8), asthenia (n = 7), neutropenia (n = 2), renal failure
(n = 2), and diarrhea (n = 1). The dose of cisplatin was reduced in
seven patients, and treatment was stopped in four patients; RT was
interrupted in six patients. An unplanned analysis revealed a trend
toward superior OS in patients who developed acneiform rash
compared with those who did not have acneiform rash. Because
of the high CR rate and despite the high toxicity rates, the authors
advocated further evaluation of this regimen in clinical trials.
Recent data have emerged that suggest docetaxel with and
without RT may be a promising treatment option for patients
with head and neck cancer. Erlotinib has also been combined
with docetaxel and RT in a phase I study of patients with
previously untreated locally advanced HNSCC (Savvides et al.,
2006). Patients received standard once-daily RT (70.2Gy total,
given as 1.8Gy/day), weekly docetaxel (15–20mg/m2) for the
duration of RT, and daily erlotinib (50–150mg/kg) for 2weeks
before, during, and up to 2 years after RT. The combination was
feasible, with 15 of 18 patients achieving CRs.
Patients with head and neck cancer who undergo surgery
and are found to have high-risk features are offered adjuvant
RT or chemoradiotherapy to reduce the risk of local recurrence.
Although cisplatin that is administered every 3weeks with con-
current RT is considered to be the standard treatment for HNSCC
(National Comprehensive Cancer Network, 2011a), the toxicity
associatedwith this approach is signiﬁcant.Many community cen-
ters treat patients withweekly cisplatin and concurrent RT because
it is better tolerated. The Spanish group Grupo de Investigación
Clínica en Oncología Radioterápica recently reported on a multi-
center, non-randomized phase I/II study investigating the addition
of erlotinib to adjuvant chemoradiotherapy in patients with sur-
gically resected locally advanced HNSCC (Arias de la Vega et al.,
2008). Twelve patients received RT at a dose of 63Gy (1.8Gy/day
over 7weeks) with weekly cisplatin (30–40mg/m2) and once-daily
erlotinib (100–150mg). The combination appeared to be feasible
in all dosing groups.Dose-limiting toxicities included grades 3 and
4 mucositis, grade 3 folliculitis, and grade 3 respiratory infection.
Median treatment duration was more than 7weeks, and no dose
reductions were required. The maximum tolerated dose (MTD) of
erlotinib was 150mg/day, of cisplatin was 30mg/m2 weekly, and
of RT was 63Gy. The phase II study evaluating this combination
is ongoing.
Meluch et al. (2009) combined concurrent chemother-
apy or RT with erlotinib and bevacizumab in a phase II
trial of patients with previously untreated locally advanced
head and neck cancer. Patients ﬁrst received two cycles of
Table 1 | Recent trials of erlotinib and radiotherapy in head and neck squamous cell carcinoma.
Trial Year Trial type N Treatment Efficacy outcome Safety outcomesa
Herchenhorn
et al. (2010)
2009 Phase I/II
single arm
31 Erlotinib+RT
+ cisplatin
Pathologic CR, 74.2% Grade 3/4 toxicities: in-ﬁeld dermatitis (52%),
nausea (48%), vomiting (39%), dysphagia
(35%), mucositis (29%), xerostomia (29%)
Savvides et al.
(2006)
2006 Phase I dose-
escalation
23 Erlotinib+RT
+docetaxel
Of 18 patients, 15 achieved
CRs
DLTs: grade 3/4 mucositis (n =2), death (n =1)
GICOR (Arias
de la Vega
et al., 2008)
2008 Phase I dose-
escalation
12 Erlotinib+RT
+ cisplatin
MTD: erlotinib, 150mg/day;
cisplatin, 30mg/m2 weekly;
RT, 63Gy
Grade 3/4 toxicities: mucositis (50%); anemia,
welt, syncope, constipation, dysphonia,
dermatitis, asthenia, respiratory infection
(8% each)
Meluch et al.
(2009)
2009 Phase II single
arm
48 RT+ chemotherapy
+erlotinib
+bevacizumab
77% ORR; 18month PFS:
85%
Grade 3/4 toxicities during induction:
neutropenia (46%), mucositis (14%), diarrhea
(14%), hand/foot syndrome (11%), neutropenic
fever (6%). Local grade 3/4 toxicities during
combined modality therapy: mucositis/
esophagitis (76%)
CR, complete response; DLT, dose-limiting toxicity; GICOR, Grupo de Investigación Clínica en Oncología Radioterápica; MTD, maximum tolerated dose; ORR, overall
response rate; PFS, progression-free survival; RT, radiotherapy.
aMost commonly reported moderate-to-severe adverse events.
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paclitaxel/carboplatin/5-ﬂuorouracil (5-FU) plus bevacizumab.
Patients (n = 48) then received concurrent RT (68.4Gy total at a
dose of 1.8 Gy/day), with paclitaxel, bevacizumab, and erlotinib
(150mg daily× 7weeks). Among the patients who completed
therapy, 56% responded after induction therapy; 77% of patients
responded after completing therapy. PFS at 18months was 85%.
Toxicities were as expected, but 76% of patients experienced
grade 3 (56%) or 4 (20%) mucositis and/or esophagitis during
concurrent therapy.
There is also interest in developing a strategy around erlotinib
maintenance therapy following deﬁnitive chemoradiotherapy for
head and neck cancer. One phase III trial being conducted in Spain
in patients with high-risk HNSCC is investigating the effect of
erlotinib 150mg/day on PFS when given as maintenance therapy
following concurrent chemoradiotherapy or RT-alone after com-
plete surgical resection (ClinicalTrials.gov, 2010, NCT00412217).
CLINICAL DATA IN NSCLC
Radiotherapy is a standard treatment for patients with unre-
sectable or locally advanced NSCLC; however, recurrence rates
with RT-alone are high, and dual-modality therapy is con-
sidered optimal for the treatment of NSCLC (National Com-
prehensive Cancer Network, 2011b). The BR.21 trial from the
National Cancer Institute of Canada Clinical Trials Group showed
that erlotinib monotherapy prolonged survival in patients with
advanced NSCLC who had progressed after standard chemother-
apy (Shepherd et al., 2005), and erlotinib is approved in this setting.
Interestingly, EGFR expression does not seem to correlate with
response to EGFR inhibitors, although an increased likelihood of
response to EGFR inhibitors was associated with never smoking,
adenocarcinoma tumor type, female gender, and acquired EGFR
adenosine triphosphate–binding site mutations in an expanded
access trial of geﬁtinib (Kim et al., 2005b). A recent analysis of
data from the BR.21 trial indicated that EGFR mutations and high
copy number are predictive of response to erlotinib (Zhu et al.,
2008). In addition, EGFR ﬂuorescence in situ hybridization score
was a signiﬁcant predictive marker of differential survival beneﬁt
from erlotinib.
Several studies in NSCLC are now underway to evaluate
erlotinib in combination with RT (Table 2). A prospective phase II
study found thatRTand concurrent erlotinibused in the treatment
of patients with unresectable NSCLC shows promising results
without an increase in toxicity (Martinez et al., 2008). Patientswith
unresectable stage I to IIIA NSCLC who were not appropriate can-
didates for chemotherapy were randomized to three-dimensional
thoracic RT at a dose of 66Gy given in 33 fractions over 6weeks or
the same dose of RT plus concomitant erlotinib at 150mg/day for
6months. Adverse events related to RT included esophagitis, radi-
ation dermatitis, and pneumonitis. The addition of erlotinib to
RT did not appear to increase RT-associated toxicities. Erlotinib-
related adverse events includedmild tomoderate skin rash (61.5%)
and diarrhea (23%). The RR was 55.5% in the RT-alone arm
compared with 83.3% in the erlotinib-plus-RT arm.
The Cancer and Leukemia Group B is conducting a phase II
trial, CALGB 30605, of nanoparticle albumin–bound paclitaxel
followed by RT and erlotinib in patients with unresectable stage
III NSCLC (ClinicalTrials.gov, 2011, NCT00553462). The study is
evaluating induction chemotherapy consisting of nab-paclitaxel
over 30min on days 1, 8, and 15 and carboplatin over 30min
on day 1. Treatment is repeated every 28 days for two courses.
Patients with no disease progression outside the planned radiation
ﬁeld will continue to receive concurrent erlotinib and RT; how-
ever, accrual to this study is currently suspended so that potential
toxicity concerns can be assessed. Another study in unresectable
stage III NSCLC is evaluating concurrent docetaxel, carboplatin,
and thoracic RT followed by erlotinib or placebo. This phase III
study was started in May 2005 and has an estimated accrual of
380 patients and a primary end point of PFS (ClinicalTrials.gov,
2009a, NCT00153803).
STEREOTACTIC RADIOSURGERY AND ERLOTINIB
Stereotactic radiosurgery is a technique for delivering a very high-
dose of RT to a (usually) small target within the body. Unlike
conventionally fractionated RT, this technique is typically deliv-
ered in fewer than ﬁve treatments. Initially, this techniquewas used
only for lesions in the brain, but technologic improvements have
Table 2 | Recent trials of erlotinib and radiotherapy in NSCLC.
Trial Year Trial type N Disease type Treatment Efficacy outcome Safety outcomesa
Martinez et al.
(2008)
2008 Phase II
randomized
23 Unresectable
stage I–IIIA
NSCLC
RT (arm 1) vs.
RT+erlotinib (arm 2)
RR: arm 1, 55.5%;
arm 2, 83.3%
Grade 3 toxicities: arm 1, pneumonitis
(4%); arm 2, radiodermatitis (8%)
Lind et al.
(2009)
2008 Phase I
single arm
11 NSCLC brain
metastases
WBRT+ concurrent
erlotinib
Of 7 patients with
follow-up imaging,
PRs in 5 and SD in 2
Grade 3–5 toxicities: interstitial lung
disease (18%), acneiform rash (9%),
fatigue (9%)
von Pawel
et al. (2008)
2008 Case
reports
2 NSCLC
recurrent brain
metastases and
parallel thoracic
progression
WBRT+ sequential
erlotinib
Survival >18 and
15months,
respectively
No severe toxicities reported
NSCLC, non-small cell lung cancer; PR, partial response; RR, response rate; RT, radiotherapy; SD, stable disease; WBRT, whole-brain radiotherapy.
aMost commonly reported moderate-to-severe adverse events.
www.frontiersin.org April 2012 | Volume 2 | Article 31 | 5
Mehta Combined radiotherapy and erlotinib
allowed it to be used in the salvage setting of recurrent tumors
virtually anywhere in the body. Because the patients considered
for treatment with stereotactic radiosurgery often have metasta-
tic disease, a greater understanding of the interaction of systemic
agents and biologic agents in combination with this high-dose RT
is needed. However, there do not appear to be any ongoing trials
evaluating stereotactic radiosurgery in combinationwith erlotinib.
There is one recent report that describes a patient with metastatic
NSCLCreceiving erlotinib during abdominal hypofractionatedRT
formetastatic spinal cord compressionwho experienced fatal acute
diarrhea (Silvano et al., 2008). It is not clear whether erlotinib con-
tributed to this complication, but certainly caution is warranted
when combining this agent with high-dose RT.
CLINICAL DATA ON BRAIN METASTASES
Whole-brain RT (WBRT) remains the standard of care for patients
with multiple intracranial metastases. There are limited published
data demonstrating the safety of deliveringWBRTwith concurrent
erlotinib. A phase I study was performed to evaluate WBRT and
concurrent erlotinib in patients with NSCLC and brain metastases
(Lind et al., 2009). No treatment-related neurotoxicity was noted
in the study. Two patients developed erlotinib-related interstitial
lung disease, contributing to death during maintenance therapy.
Five of 11 patients developed acneiform rash, all of whom survived
for more than 150 days. Notably, the intracranial disease control
rate in patients with imaging scans was 100% (7/7) at 3months,
with ﬁve patients having a partial response (PR); intracranial pro-
gressionwas conﬁrmed in a single patient with clinical progression
on magnetic resonance imaging at 204 days. In addition to these
data, a recent report on two patients with previously irradiated,
recurrent NSCLC metastases to the brain indicated that these
patients survived 18 and 15months after occurrence of cranial
disease when treated with erlotinib, representing an encouraging
survival outcome (von Pawel et al., 2008).
The Radiation Therapy Oncology Group is conducting a ran-
domizedphase III trial,RTOG-0320, to evaluateWBRTand stereo-
tactic radiosurgery with or without temozolomide or erlotinib in
patients with NSCLC and one to three brain metastases (Clinical-
Trials.gov, 2009b, NCT00096265). The projected accrual of this
study is 380 patients. Arm 1 will receive WBRT followed by stereo-
tactic radiosurgery, arm 2 will receive similar RT as arm 1 plus oral
temozolomide (after RT, any chemotherapy regimen is allowed),
and arm 3 will receive similar RT as arm 1 plus erlotinib (after
RT, any chemotherapy except temozolomide is allowed). Erlotinib
will be continued for a maximum of 6months unless intracranial
progression is evident or the patient cannot tolerate treatment.
CLINICAL DATA IN GBM
Fractionated external beam RT after maximal excision or biopsy
is standard therapy for GBM and other high-grade astrocytomas
(National Comprehensive Cancer Network, 2011c). The outcome
for most of these patients, however, remains poor. An increasing
amount of molecular data suggests that erlotinib might be effec-
tive in this disease. EGFR is ampliﬁed or overexpressed in up to
60% of GBMs (Salomon et al., 1995). In addition, mutations of
the EGFR gene may be present in as many as 50–70% of EGFR-
overexpressing tumors.Most genemutations associatedwithGBM
affect the extracellular domain and include a large deletion in
exons 2–7, resulting in a variant receptor called EGFRvIII, which
has ligand-independent kinase activity. The presence of EGFRvIII
appears to be associatedwith aworse prognosis inGBM thanwhen
this variant receptor is absent (Heimberger et al., 2005).
The molecular data have prompted investigations into the role
of erlotinib in the treatment of patients with GBM (Table 3). A
phase II study recently evaluated erlotinib in combination with
carboplatin (but not RT) in patients with GBM and no more than
two prior relapses (de Groot et al., 2008). Carboplatin was given
on day 1 of every 28-day cycle (to a dose of area under the curve
6mg/mL·min). The dose of erlotinib was escalated from 150 to
200mg/day when tolerated. In 43 evaluable patients, one PR was
observed, and 47%of patients achieved SD for amean of 12weeks.
Median PFS was 9weeks, and median OS was 30weeks. Grade 3 or
4 toxicities included fatigue, leukopenia, thrombocytopenia, and
rash (requiring dose reduction). The activity of this combination
appears to be modest, although future trials may show a beneﬁt
with erlotinib-plus-RT in GBM when patients are selected on the
basis of molecular or clinical characteristics.
N0177, a phase II trial led by the North Central Cancer
Treatment Group, evaluated erlotinib in combination with temo-
zolomide and RT (Brown et al., 2008). A total of 97 patients
with GBM underwent resection or biopsy followed by 1week of
erlotinib 150mg/day, followed by erlotinib with temozolomide
75mg/m2/day and RT to a total of 60Gy. This was then followed
by up to six cycles of adjuvant temozolomide 200mg/m2/day
for 5 days every 28 days. Sixty-one percent of these patients were
alive after 1 year, and median survival was 15months. However,
no beneﬁt was observed when these results were compared with
historical controls from the RT-plus-temozolomide arm of the
European Organisation for Research and Treatment of Cancer
26981 trial. In addition, EGFR expression in this trial did not cor-
relate with improved outcomes. Although the theoretic rationale
for incorporating erlotinib into standard RT and temozolomide
is compelling, the clinical data supporting this regimen must be
considered preliminary.
Another phase II study evaluated erlotinib with RT and temo-
zolomide in 65patientswithnewlydiagnosedGBMorgliosarcoma
(Prados et al., 2009). Patients received 100mg/day of erlotinib
during RT and 150mg/day after RT. Patients receiving enzyme-
inducing antiepileptic drugs received 200mg/day of erlotinib dur-
ing RT and 300mg/day after RT. Temozolomide was given during
and after RT. The median survival in this study was 19.3months
compared with 14.1months in the combined historical control
studies, with a hazard ratio for survival (treated/control) of 0.64
(95% conﬁdence interval, 0.45–0.91). These ﬁndings suggest that
further studies of this combination are warranted.
CLINICAL DATA IN ESOPHAGEAL CANCER
EGFR protein expression is present in approximately 30–70%
of esophageal carcinomas and has been correlated with poor
patient prognosis and inferior response to conventional treatment
(Hanawa et al., 2006;Wang et al., 2007). In addition,EGFRampliﬁ-
cation is present in approximately 15% of esophageal carcinomas,
but EGFR mutations are rare (Hanawa et al., 2006). In a phase II
study of patients with gastroesophageal junction/cardia and distal
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Table 3 | Recent trials of erlotinib and RT in GBM, esophageal cancer, and pancreatic cancer.
Trial Year Trial type N Disease type Treatment Efficacy outcome Safety outcomesa
de Groot et al.
(2008)
2008 Phase II single
arm
43 Recurrent
GBM
Carboplatin
+erlotinib (no
RT)
SD, 47% for average
of 12weeks; median
PFS, 9weeks
Grade 3/4 toxicities: lymphopenia
(47%), neutropenia (35%), thrombo-
cytopenia (35%), fatigue (23%). One
treatment-related death
Brown et al.
(2008)
2008 Phase II
compared with
historical
controls
97 GBM Erlotinib
+ temozolomide
+RT
Median survival,
15months; no
beneﬁt vs. historical
controls
Grade ≥2 toxicities: rash (42%), diar-
rhea (10%)
Dobelbower
et al. (2006)
2006 Phase I dose-
escalation
11 Esophageal
cancer
Concurrent
erlotinib
+5-FU
+ cisplatin
+RT
Feasible
combination; 2
discontinuations not
related to erlotinib
Grade 3/4 toxicities: leukopenia (36%),
dehydration (27%), neutropenia (18%),
esophagitis (18%)
Li et al. (2010) 2009 Phase II 24 Locally
advanced
esophageal
cancer
Concurrent
erlotinib
+paclitaxel
+ cisplatin+RT
11 CRs (46%), 11
PRs (46%)
Acute grade 3/4 toxicities: esophagitis
(21%), leukopenia (17%), thrombocy-
topenia (8%), skin rash (4%)
Iannitti et al.
(2005)
2005 Phase I dose-
escalation
13 Locally
advanced
pancreatic
cancer
Erlotinib
+gemcitabine
+paclitaxel+RT,
followed by
maintenance
erlotinib
Median survival,
14.0months; 46%
PR
Acute grade 3 toxicities (n =17): dehy-
dration (18%), thrombosis (18%), diar-
rhea (12%), hypersensitivity (12%)
Cardenes et al.
(2009)
2009 Pilot 8 Potentially
resectable
pancreatic
cancer
Neoadjuvant
gemcitabine
+erlotinib+RT
No CRs; 2
downstaged prior to
surgery; 1 year PFS;
and OS rates of 50
and 75%,
respectively
Preoperative grade 3 toxicities: liver dys-
function, vomiting, neutropenia (13%
each)
Duffy et al.
(2008)
2008 Phase I 20 Non-operable
pancreatic
adenocarci-
noma
Erlotinib
+gemcitabine
+RT
No CRs; 35% PR;
and 53% SD
Grade 3/4 toxicities during chemoradia-
tion: lymphopenia (100%), neutropenia
(35%), thrombocytopenia (25%), diar-
rhea (15%)
5-FU, 5-ﬂuorouracil; CR, complete response; DLT, dose-limiting toxicity; GBM, glioblastoma; OS, overall survival; PFS, progression-free survival; PR, partial response;
RT, radiotherapy; SD, stable disease.
aMost commonly reported moderate-to-severe adverse events.
gastric adenocarcinomas, the activity of erlotinib as monotherapy
in esophageal cancer was modest (objective RR, 9%) (Dragovich
et al., 2006).
The combination of erlotinib with chemoradiotherapy is cur-
rently being evaluated (see Table 3). Dobelbower et al. (2006)
investigated RT, 5-FU, cisplatin, and erlotinib in a phase I trial
of 11 patients with esophageal cancer. Patients were assigned to
receive a dose of 50, 100, or 150mg/day erlotinib given concur-
rently with RT (50.4Gy at 1.8 Gy/day), cisplatin (75mg/m2, days 8
and 36), and 5-FU (1000mg/m2, days 8–11 and 36–39). Erlotinib
was well tolerated, with the main toxicities being diarrhea, skin
rash (grade 1, 54.5%), nausea, and dehydration. All patients
experienced esophagitis, mostly grades 1 and 2, during treatment.
A phase II study by Li et al. (2010) found that a regimen of
RT with concurrent paclitaxel, cisplatin, and erlotinib for patients
with locally advanced esophageal carcinoma had antitumor activ-
ity but was accompanied by signiﬁcant but manageable toxicity.
Twenty-four patients received 60Gy of RT in 30 fractions along
withpaclitaxel 135mg/m2 ondays 1 and29 and cisplatin 20mg/m2
on days 1, 2, 3, 29, 30, and 31, with dose adjustments as needed.
Erlotinib 150mg/day was given concurrently on days 1 through
42. Acute grade 3 toxicities included leukopenia, esophagitis, and
skin rash; four patients were unable to complete both cycles of
chemotherapy. Twenty-two patients responded to therapy, includ-
ing 11 patients with CRs. At median follow-up of 18.7months,
eight patients had distant recurrence; one of them also had failure
at the site of the original lesion. The 2-year locoregional control
andOS rateswere 87.5 and 70.1%, respectively. These initial results
suggest that this regimenhas potential to enhance local control and
improve survival in patients with esophageal cancer.
www.frontiersin.org April 2012 | Volume 2 | Article 31 | 7
Mehta Combined radiotherapy and erlotinib
CLINICAL DATA IN PANCREATIC CANCER
Pancreatic cancer remains a difﬁcult disease to treat, and the role
of RT in its treatment is controversial. Recent publications have
suggested a survival improvement for some patients receiving
chemoradiotherapy compared with observation in the adjuvant
setting (Berger et al., 2008; Hsu et al., 2010). The combination
of erlotinib with concurrent chemoradiation in locally advanced
pancreatic cancer has demonstrated promising tumor RRs in the
range of 30–40%, with acceptable toxicity and median survival
times in excess of 14months (Iannitti et al., 2005).
The ﬁnding that erlotinib in combination with gemcitabine
improves outcome and survival in patients with metastatic pan-
creatic cancer (Moore et al., 2007) prompted the initiation of
studies evaluating the role of RT and concurrent erlotinib in
this disease (see Table 3). Iannitti et al. (2005) conducted a
phase I trial to determine the MTD of erlotinib (50–100mg/day)
that could be used with concurrent gemcitabine, paclitaxel,
and RT for patients with locally advanced pancreatic cancer.
Seventeen patients, 13 with locally advanced disease and four
with positive margins after resection, received 50.4Gy of RT
in increments of 1.8 Gy/day along with gemcitabine 75mg/m2
and paclitaxel 40mg/m2 once per week for 6weeks. Mainte-
nance erlotinib 150mg/day was well tolerated; however, when
the erlotinib dose was increased to 75mg/day or more during
chemoradiation, dose-limiting toxicities included diarrhea, dehy-
dration, myelosuppression, rash, and small-bowel stricture. In
patients with locally advanced disease, the median survival was
14.0months, with 46% achieving PRs, indicating that the use of
erlotinib plus chemoradiation in this setting may warrant further
study.
In a small pilot study, the combination of neoadjuvant gemc-
itabine, erlotinib, and short-course RT (30Gy) was investigated
in eight evaluable patients with potentially resectable pancre-
atic cancer (Cardenes et al., 2009). Patients received 2weeks of
erlotinib 100mg/day, gemcitabine 300mg/m2/week, and 30Gy of
RT in 3Gy/day fractions. Preoperative grade 3 or 4 toxicities were
vomiting, neutropenia, and hepatotoxicity, which occurred in one
patient each. All patients were able to undergo surgery. Hema-
tologic toxicities were observed in three patients postoperatively,
and one patient had delayed gastric emptying. Prior to surgery, no
pathologic CRs were observed, but two patients had downstaged
disease and no changes in tumor stage were present in the remain-
ing six patients. At a median follow-up of 15months, three deaths
were attributed to distant and/or local recurrences; ﬁve of the eight
patients were alive.
Another study sought to determine the MTD of erlotinib when
administered concurrently with twice-weekly gemcitabine and RT
for locally advanced pancreatic cancer (Duffy et al., 2008). Twenty
patients were treated with daily erlotinib in combination with
gemcitabine 40mg/m2 over 30min twice-weekly and RT deliv-
ered at a dose of 1.8 Gy/day in 28 fractions over 5.5 weeks for
a total of 50.4Gy. After chemoradiation, patients received main-
tenance weekly gemcitabine 1000mg/m2 on days 1 and 8 of a
21-day cycle and daily erlotinib for four cycles. The MTD of
erlotinib in combination with twice-weekly gemcitabine-based
chemoradiation was determined to be 100mg/day. The PR rate
was 35%, and 53% of patients had SD. The median survival for
all patients was 18.7months. Together, these ﬁndings indicate that
RT in combination with erlotinib and chemotherapy is feasible in
this setting for which few effective treatment options exist.
CONSIDERATIONS FOR CLINICAL PRACTICE
Many questions remain with respect to the use of erlotinib in
combination with RT. One such question is whether erlotinib
should be administered concurrently with RT. Although stopping
erlotinib would avoid some of the potentially overlapping toxici-
ties that could occur with coadministration, erlotinib and RT may
act synergistically and provide an additional beneﬁt together com-
pared with using either approach alone. Such a beneﬁt, however,
has yet to be conﬁrmed in randomized clinical trials. Most trials
have evaluated erlotinib given simultaneously with RT, as well as
with maintenance erlotinib after RT. The simultaneous approach
appears to be feasible; however, a case-by-case evaluation of each
patient is needed because no strong evidence exists for either a
sequential or concurrent approach.
Another issue to consider is the duration and dose of RT to
use with erlotinib and whether these parameters should be mod-
iﬁed compared with using RT-alone. In addition, RT treatment
approaches vary among institutions (National Comprehensive
Cancer Network, 2011a). Combining erlotinib with RT adds to the
complexity of treatment decisions, and each patient case should
be considered individually.
Clinical trials investigating the efﬁcacy and safety of erlotinib
and RT in patients with cancer have not included EGFR sta-
tus as part of the eligibility criteria. Moreover, few biomarker
analyses have been conducted to evaluate the association between
EGFR expression and survival parameters in these studies, in
part, because of limited sample size and the lack of correla-
tion established in earlier clinical studies of erlotinib without
RT. In the N0177 trial of erlotinib with temozolomide and RT
in patients with GBM, molecular analyses did not show an associ-
ation between EGFR expression and outcome (Brown et al., 2008).
Given the complex interaction between EGFR signaling and radi-
ation response, additional biomarker studies are needed to deﬁne
whether there is a correlation between erlotinib and RT treatment
with PFS and OS outcomes.
Another consideration is how erlotinib treatment may affect
the tolerance of normal adjacent organs that are exposed to RT.
Erlotinib and RT may interact negatively in terms of skin reaction.
For example, recent case reports suggest that RT can affect the
timing and severity of erlotinib-induced cutaneous adverse events
(Mitra and Simcock, 2006; Gerber et al., 2007; Lacouture et al.,
2007).
Erlotinib-induced rash may heighten or inﬂuence the sensitiv-
ity of the skin to irradiation effects.WhenRT is administered prior
to erlotinib, the appearance of rash may be delayed in the area of
RT but becomes apparent within a few weeks to months after RT
has ended. This phenomenonwas demonstrated by a case inwhich
a preirradiated area on the back of a 56-year-old man with ade-
nocarcinoma was spared the development of an erlotinib-induced
papulopustular rash for 3weeks compared with the surrounding
area (Mitra and Simcock, 2006). RT (64Gy in 32 fractions) had
been initiated approximately 12months before erlotinib therapy.
Similarly, a 55-year-old woman with metastatic NSCLC developed
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a papulopustular rash on the face,upper extremities, and elsewhere
1week after initiation of erlotinib 150mg/day (Gerber et al., 2007);
however, a rectangular ﬁeld irradiated with 32Gy (single doses of
2Gy) 2months earlier did not develop rash until 4months after
irradiation and 2months after initiation of erlotinib. In a third
report, Lacouture et al. (2007) described the case of an 84-year-old
woman with NSCLC who received 2weeks of RT (30Gy in 10 frac-
tions) on her chest just before initiation of erlotinib.After 5 days of
erlotinib therapy, amild papulopustular rash appeared on her face,
but a severe rash was also observed in the preirradiated area on
her chest. Further studies are needed to investigate themechanisms
underlying the transient effects of RT on erlotinib-induced rash.
It may be caused by a transient immunosuppression owing to a
loss of Langerhans and other immunocompetent cells or a tempo-
rary depletion of EGFR-containing stem cells in the basal layer of
the irradiated area (Mitra and Simcock, 2006). Although erlotinib
might also enhance RT-related adverse events and vice versa, the
combination of erlotinib with RT has not seemingly resulted in
additional unexpected adverse events on the basis of investigations
to date. In clinical trials evaluating erlotinib with RT, hematologic
toxicities, mucositis, and gastrointestinal toxicities (e.g., diarrhea,
vomiting) are among the most commonly reported moderate-to-
severe adverse events. However, since the majority of these trials
also included a chemotherapy component, the safety of these
regimens reﬂects the contribution and interaction of all three
modalities.
CONCLUSION
Trials thus far have evaluated RT and erlotinib in an array of cancer
types, includingHNSCC,NSCLC,andmany others. Phase III trials
are underway that will help provide more information about the
optimal way to combine these two treatment modalities. No strik-
ing beneﬁt has been observed in any study combining erlotinib
and RT, but modest improvements have been reported with this
approach. Certainly, adverse events for either approach do not
seem tobe exacerbated, and toxicities have beenmanageable. Thus,
based on the evidence, further investigation into the combination
of erlotinib and RT is warranted, and results from current studies
are eagerly awaited. Importantly, each patient should be treated
on a case-by-case basis with careful consideration of individual
patient preferences and disease characteristics.
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